Status
Conditions
Treatments
About
Cardiac resynchronization therapy (CRT) is a device treatment for patients with heart failure which cannot be managed by medications alone. CRT can help the heart contract more efficiently and improve the pumping function. However, many patients do not benefit from this treatment. Therefore, a better selection tool will help us to determine the most suitable patients to receive this treatment. A new measure of pumping function of the heart called: first-phase ejection fraction or EF1 has been shown a good tool to select suitable patients for CRT. EF1 is a sensitive measurement of heart function and can be easily measured by echocardiography (an ultrasound heart scan).
The purpose of this study is to examine whether this new measurement (EF1) can predict outcomes and response to CRT treatment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 18 years or older
On optimal medical therapy for heart failure
Meets standard guideline criteria for CRT (including conduction system pacing), specifically:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
400 participants in 2 patient groups
Loading...
Central trial contact
Haotian Gu, PhD; Phil Chowienczyk, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal